Expert consensus on the management of adverse events of CDK4/6 inhibitors in breast cancer.
10.3760/cma.j.cn112152-20220825-00578
- Author:
Rui GE
1
;
Bi Yun WANG
2
;
Ze Fei JIANG
3
Author Information
1. Department of General Surgery, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, China.
2. Department of Medical Oncology, Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China.
3. Department of Breast Oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.
- Collective Name:Expert Group of Chinese Society of Clinical Oncology Breast Cancer
- Publication Type:Journal Article
- Keywords:
Adverse events;
Breast neoplasms;
CDK4/6 inhibitor;
Expert consensus;
Hormone receptor positive
- MeSH:
Female;
Humans;
Aminopyridines/adverse effects*;
Antineoplastic Agents/adverse effects*;
Breast Neoplasms/drug therapy*;
Consensus;
Cyclin-Dependent Kinase 4/antagonists & inhibitors*;
Protein Kinase Inhibitors/adverse effects*;
Cyclin-Dependent Kinase 6/antagonists & inhibitors*
- From:
Chinese Journal of Oncology
2022;44(12):1296-1304
- CountryChina
- Language:Chinese
-
Abstract:
Cyclin-dependent kinases 4/6 (CDK4/6) inhibitors are anti-tumor agents for the treatment of hormone receptor-positive breast cancer. Palbociclib, abemaciclib and dalpiciclib have been approved for the treatment of breast cancer in China. Common adverse effects of CDK4/6 inhibitors include bone marrow suppression, gastrointestinal toxicities, liver dysfunction, and skin or subcutaneous tissue adverse reactions (AEs). The Breast Cancer Expert Group of Chinese Society of Clinical Oncology (CSCO) summarized the incidence, clinical manifestations, and grading of the AEs. This expert consensus reports measures of AE management on the basis of experience of clinical practice and the latest advances worldwide, aiming to guide clinical practice by the way of managing AE and help to choose the best treatment regimen.
